Both subgroups exhibited decreased levels of Aβ42 compared to non-AD controls; one subgroup had elevated levels of tau and phosphorylated tau (Aβ+/tau+, n = 60), while the other showed normal levels (Aβ+/tau-, n = 28 patients) (supplemental Fig. S1). Here, MAPT is linked to Alzheimer disease.